Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C18H24N4O· HCl
CAS Number:
Molecular Weight:
348.87
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Quality Level
assay
≥98% (HPLC)
form
solid
storage condition
desiccated
color
white to off-white
mp
284.0-290.0 °C
solubility
H2O: >10 mg/mL
originator
Roche
storage temp.
room temp
SMILES string
Cl.CN1[C@H]2CCC[C@@H]1C[C@@H](C2)NC(=O)c3nn(C)c4ccccc34
InChI
1S/C18H24N4O.ClH/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17;/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23);1H/t12-,13+,14-;
InChI key
QYZRTBKYBJRGJB-WQTKJZBYSA-N
Biochem/physiol Actions
Granisetron hydrochloride helps to block nausea/emesis and abdominal pain in irritable bowel syndrome, that is stimulated by chemotherapy.
Granisetron hydrochloride is a serotonin 5-HT3 receptor antagonist and antiemetic.
Features and Benefits
This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Still not finding the right product?
Explore all of our products under Granisetron hydrochloride
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Alterations of colonic sensitivity and gastric dysmotility after acute cisplatin and granisetron
Martin R, et al.
Neurogastroenterology and Motility, e13499-e13499 (2018)
Joseph A Roscoe et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30(27), 3389-3395 (2012-08-24)
We conducted a double-blind randomized clinical trial of the following four regimens for controlling delayed nausea (DN): group 1: palonosetron + dexamethasone on day 1 with prochlorperazine on days 2 and 3; group 2: granisetron + dexamethasone on day 1
J Vardy et al.
Breast cancer research and treatment, 136(1), 143-151 (2012-09-08)
Uncertainty remains about the optimal anti-emetic regimen for control of delayed nausea and vomiting after adjuvant chemotherapy for breast cancer. Many patients receive dexamethasone but complain of insomnia, anxiety/agitation, and indigestion. The aim was to determine if patients receiving chemotherapy
Global Trade Item Number
| SKU | GTIN |
|---|---|
| G3796-10MG | 04061833630204 |
| G3796-50MG | 04061832082202 |
